Table 1.
Patient and tumour characteristics
| Transperineal APE N = 32 | ||
|---|---|---|
| Sex | Male (%) | 24 (75.0) |
| Female (%) | 8 (25.0) | |
| BMI kg/m2 (mean) (± SD) | 26.4 (3.3) | |
| Age,years (mean) (± SD) | 65.7 (12.8) | |
| ASA class | I | 1 (3.1) |
| II | 25 (78.1) | |
| III | 6 (18.8) | |
| Tumour height from ARJ (cm)* | Mean (± SD) | 0.50 (0.87) |
| Median (range) | 0 (0–3.0) | |
| T-stage (%) | cTis | 1 (3.1) |
| cT2 | 7 (21.9) | |
| cT3 | 17 (53.1) | |
| cT4b | 7 (21.9) | |
| N-stage (%) | N0 | 18 (56.3) |
| N1 | 8 (25.0) | |
| N2 | 6 (18.8) | |
| M-stage (%) | M + | 1 (3.1)** |
| Mesorectal fascia involved | Yes | 21 (65.6) |
| No | 11 (34.4) | |
| EMVI | Yes | 8 (25.0) |
| No | 18 (56.3) | |
| Unknown | 6 (18.8) | |
| Ingrowth | No | 16 (50.0) |
| Spinctercomplex | 10 (31.3) | |
| M. levator ani | 4 (12.5) | |
| Prostate / vagina | 2 (6.3) | |
| Neoadjuvant radiotherapy (%) | No | 9 (28.1) |
| 5 × 5 short interval | 3 (9.4) | |
| long course Chemorad | 20 (62.5) |
Numbers in parenthesis are percentages, unless mentioned otherwise
BMI body mass index, SD standard deviation, ASA American Society of Anesthesiologists, RT radiotherapy, CRT chemoradiotherapy, ARJ anorectal junction
*22 of 32 located at or below level of ARJ
**Para-aortic M +